Free tool
FAERS Monitor: Gleevec
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021588 or its brand name (Gleevec, Imatinib Mesylate). Reports on generic versions are filed under their own applications.
Reports
27,809
Serious
20,991
75% of reports
Hospitalization
6,162
Death reported
6,801
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death4,640
- nausea2,144
- diarrhoea1,773
- fatigue1,533
- drug ineffective1,396
- vomiting1,291
- malaise1,082
- rash1,003
- dyspnoea995
- muscle spasms862
- neoplasm malignant847
- asthenia806
- pyrexia774
- anaemia720
- malignant neoplasm progression686
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 638 |
| 2005 | 712 |
| 2006 | 687 |
| 2007 | 717 |
| 2008 | 727 |
| 2009 | 1,136 |
| 2010 | 1,568 |
| 2011 | 3,282 |
| 2012 | 3,332 |
| 2013 | 1,010 |
| 2014 | 619 |
| 2015 | 1,009 |
| 2016 | 1,668 |
| 2017 | 1,518 |
| 2018 | 1,567 |
| 2019 | 1,761 |
| 2020 | 1,390 |
| 2021 | 1,147 |
| 2022 | 1,012 |
| 2023 | 1,022 |
| 2024 | 623 |
| 2025 | 363 |
| 2026 | 296 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,026,350 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neoplasm malignantSignal | 847 | 9.7 | 9.1 | 6,544 |
| malignant neoplasm progressionSignal | 686 | 5.1 | 4.7 | 2,249 |
| deathSignal | 4,640 | 4.1 | 4.0 | 11,231 |
| muscle spasmsSignal | 862 | 3.6 | 3.3 | 1,594 |
| anaemiaSignal | 720 | 2.9 | 2.7 | 875 |
| diarrhoeaSignal | 1,773 | 2.1 | 2.0 | 1,022 |
| vomitingSignal | 1,291 | 2.1 | 2.0 | 737 |
| nauseaSignal | 2,144 | 2.1 | 2.0 | 1,197 |
| malaise | 1,082 | 1.9 | 1.8 | 444 |
| rash | 1,003 | 1.7 | 1.6 | 322 |
| pyrexia | 774 | 1.7 | 1.6 | 222 |
| asthenia | 806 | 1.6 | 1.5 | 195 |
| fatigue | 1,533 | 1.5 | 1.4 | 256 |
| dyspnoea | 995 | 1.3 | 1.3 | 83 |
| drug ineffective | 1,396 | 0.8 | 0.8 | 73 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.